Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBOT will be evaluated by the primary care team and hyperbaric physician.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 40 participants
Primary Purpose: Treatment
Actual Study Start Date: April 6, 2020
Estimated Study Completion Date: July 2020
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, age > 18 years
- Positive COVID 19 test
- Respiratory compromise defined by SpO2 <93%
- Ability to sign informed consent
An individual who meets any of the following criteria will be excluded from participation in this study:
- Untreated Pneumothorax
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.